Study of IL-12 Agonists in Macrophages from Patients with Healing and Non-Healing Forms of Cutaneous leishmaniasis

Document Type : Original Article (s)

Authors

1 Department of Parasitology and Mycology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 Associate Professor, Skin Disease and Leishmaniasis Research Center AND Department of Parasitology and Mycology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

3 PhD Student, Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

4 PhD Student, Department of Parasitology and Mycology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

5 Professor, Center for Research and Training in Skin Disease and Leprosy, Tehran University of Medical Sciences, Tehran, Iran

6 Associate Professor, Skin and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, Iran

Abstract

Background: Cutaneous leishmaniasis (CL) is a self-healing disease; however, due to some reasons, in a few cases the lesion develops to a non-healing form of disease. The initial encounter of Leishmania with its host’s innate immune system is important in the outcome of infection. Although, tremendous data is available in murine model of leishmaniasis but immunological surrogate marker(s) of healing and protection in human is not yet well-defined. In this study, the level of IL-23 and IL-27 produced by peripheral blood derived macrophages from patients with healing or non-healing form of cutaneous leishmaniasis lesion were determined to explore whether IL-23 or IL-27 plays a protection role in healing process of cutaneous lesions induced by Leishmania major (L. major).Methods: 26 six patients resident in Isfahan Province, Iran, with healing or non-healing forms of cutaneous leishmaniasis caused by L. major were selected. In-vitro productions of IL-23 and IL-27 by peripheral blood derived macrophages, before and after stimulation with live L. major (MRHO/IR/75/ER) promastigotes were evaluated in these two groups and control group using the enzyme-linked immunosorbent assay (ELISA) method.Findings: The mean difference production of IL-23 and IL-27 from macrophages of patients with healing form of lesion was significantly higher than patients with non-healing form. The levels of IL-23 and IL-27 in culture supernatants before and after stimulation in healing form of disease was significantly higher than non-healing form (P < 0.001).Conclusion: It seems that IL-12 agonists might play a protection role in human leishmaniasis and further studies are needed to understand the role of these cytokine in cutaneous leishmaniasis.

Keywords

References

  1. Dowlati Y. Cutaneous leishmaniasis: clinical aspect. Clin Dermatol 1996; 14(5): 425-31.
  2. Herwaldt BL. Leishmaniasis. Lancet 1999; 354(9185): 1191-9.
  3. Bailey MS, Lockwood DN. Cutaneous leishma-niasis. Clin Dermatol 2007; 25(2): 203-11.
  4. von SE. Cutaneous Leishmania infection: progress in pathogenesis research and experimental therapy. Exp Dermatol 2007; 16(4): 340-6.
  5. Lohoff M, Gessner A, Bogdan C, Rollinghoff M. Experimental murine leishmaniasis and the Th1/Th2 cell concept. Tokai J Exp Clin Med 1998; 23(6): 347-50.
  6. Muller I, Fruth U, Louis JA. Immunobiology of experimental leishmaniasis. Med Microbiol Immunol 1992; 181(1): 1-12.
  7. Sacks D, Noben-Trauth N. The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol 2002; 2(11): 845-58.
  8. Ajdary S, Alimohammadian MH, Eslami MB, Kemp K, Kharazmi A. Comparison of the immune profile of nonhealing cutaneous Leishmaniasis patients with those with active lesions and those who have recovered from infection. Infect Immun 2000; 68(4): 1760-4.
  9. Ajdary S, Jafari-Shakib R, Riazi-Rad F, Khamesipour A. Soluble CD26 and CD30 levels in patients with anthroponotic cutaneous leishmaniasis. J Infect 2007; 55(1): 75-8.
  10. Mahmoodi M, Rajabalian S, Fekri A, Esfandiarpour I. Evaluation of In Vitro Production of IFN-gamma, IL-10, IL-12 and IL-13 by Blood Cells in Patients with Cutaneous Leishmaniasis Lesions. Iran J Allergy Asthma Immunol 2005; 4(1): 15-21.
  11. Habibi GR, Khamesipour A, McMaster WR, Mahboudi F. Cytokine gene expression in healing and non-healing cases of cutaneous leishmaniasis in response to in vitro stimulation with recombinant gp63 using semi-quantitative RT-PCR. Scand J Immunol 2001; 54(4): 414-20.
  12. Jafari-Shakib R, Shokrgozar MA, Nassiri-Kashani M, Malakafzali B, Nikbin B, Khamesipour A. Plasma sCD26 and sCD30 levels in cutaneous leishmaniasis. Acta Trop 2009; 109(1): 61-3.
  13. Bogdan C, Gessner A, Rollinghoff M. Cytokines in leishmaniasis: a complex network of stimulatory and inhibitory interactions. Immunobiology 1993; 189(3-4): 356-96.
  14. Hunter CA, Villarino A, Artis D, Scott P. The role of IL-27 in the development of T-cell responses during parasitic infections. Immunol Rev 2004; 202: 106-14.
  15. Tan ZY, Bealgey KW, Fang Y, Gong YM, Bao S. Interleukin-23: immunological roles and clinical implications. Int J Biochem Cell Biol 2009; 41(4): 733-5.
  16. Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000; 13(5): 715-25.
  17. Pflanz S, Timans JC, Cheung J, Rosales R, Kanzler H, Gilbert J, et al. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4(+) T cells. Immunity 2002; 16(6): 779-90.
  18. Yoshimoto T, Yoshimoto T, Yasuda K, Mizuguchi J, Nakanishi K. IL-27 suppresses Th2 cell development and Th2 cytokines production from polarized Th2 cells: a novel therapeutic way for Th2-mediated allergic inflammation. J Immunol 2007; 179(7): 4415-23.
  19. Yoshida H, Miyazaki Y. Regulation of immune responses by interleukin-27. Immunol Rev 2008; 226: 234-47.
  20. Watford WT, Hissong BD, Bream JH, Kanno Y, Muul L, O'Shea JJ. Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4. Immunol Rev 2004; 202: 139-56.
  21. Watford WT, Moriguchi M, Morinobu A, O'Shea JJ. The biology of IL-12: coordinating innate and adaptive immune responses. Cytokine Growth Factor Rev 2003; 14(5): 361-8.
  22. Beadling C, Slifka MK. Regulation of innate and adaptive immune responses by the related cytokines IL-12, IL-23, and IL-27. Arch Immunol Ther Exp (Warsz ) 2006; 54(1): 15-24.
  23. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004; 4(7): 499-511.
  24. Romagnani S. Regulation of the T cell response. Clin Exp Allergy 2006; 36(11): 1357-66.
  25. Rogers KA, DeKrey GK, Mbow ML, Gillespie RD, Brodskyn CI, Titus RG. Type 1 and type 2 responses to Leishmania major. FEMS Microbiol Lett 2002; 209(1): 1-7.
  26. Yoshida H, Hamano S, Senaldi G, Covey T, Faggioni R, Mu S, et al. WSX-1 is required for the initiation of Th1 responses and resistance to L. major infection. Immunity 2001; 15(4): 569-78.
  27. Lieberman LA, Cardillo F, Owyang AM, Rennick DM, Cua DJ, Kastelein RA, et al. IL-23 provides a limited mechanism of resistance to acute toxoplasmosis in the absence of IL-12. J Immunol 2004; 173(3): 1887-93.
  28. Smits HH, van Beelen AJ, Hessle C, Westland R, de JE, Soeteman E, et al. Commensal Gram-negative bacteria prime human dendritic cells for enhanced IL-23 and IL-27 expression and enhanced Th1 development. Eur J Immunol 2004; 34(5): 1371-80.
  29. Scharton-Kersten T, Afonso LC, Wysocka M, Trinchieri G, Scott P. IL-12 is required for natural killer cell activation and subsequent T helper 1 cell development in experimental leishmaniasis. J Immunol 1995; 154(10): 5320-30.
  30. Wang ZE, Zheng S, Corry DB, Dalton DK, Seder RA, Reiner SL, et al. Interferon gamma-independent effects of interleukin 12 administered during acute or established infection due to Leishmania major. Proc Natl Acad Sci U S A 1994; 91(26): 12932-6.
Journal of Isfahan Medical School
Volume 31, Issue 252 - Serial Number 252
July and August 2013
Pages 1435-1442

Files

History

  • Receive Date: 09 January 2013
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics